Ai Feedback
Exact(5)
The prognostic value of molecular subtype based on immunohistochemistry is uncertain within the group of young breast cancer patients.
The BluePrint 80-gene classifier identifies "functional" molecular subtype based on intact molecular pathways associated with concordant mRNA and protein expression (1).
We classified 5,687 invasive breast cancers by molecular subtype based on immunohistochemical expression of estrogen-receptor (ER), progesterone-receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 proliferation index.
A total of 58 kinases have been classified as receptor type and are listed in Additional file 2. Each of these kinases was assessed in the basal molecular subtype based on the three classifiers (ssp2003, ssp2006 and PAM50).
A multivariate logistic regression model was built to examine the associations between pCR and age, menopausal status, tumor stage (T1 vs. T2 vs. T3), N stage (N0 vs. N1), molecular subtype based on tumor receptor status (ER-positive vs. triple-negative vsHER2-positive), histology (ductal vs. lobular vs. other).
Similar(55)
High grade gliomas (HGGs) have been classified into three molecular subtypes based on similarity to defined expression signatures: Proneural (PN), Proliferative (Prolif) and Mesenchymal (MES) [32].
Worldwide, breast cancer is classified into molecular subtypes based on estrogen receptor (ER) and HER2 status.
Breast cancer samples were categorized into molecular subtypes based on immunohistochemical profiles.
A method of molecular subtyping based on 783 probe-sets was established and validated.
Breast cancers of the luminal A and luminal B molecular subtypes (based on gene expression profiling) are typically ER+.
The molecular subtypes, based on gene expression profiles, reflect underlying biological behavior of tumors and differ markedly in prognosis [ 4- 6].
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.
Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com